Your browser doesn't support javascript.
loading
Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?
Bhoday, J; Glimelius, B; Tait, D; Glynne-Jones, R; Adams, R; Brown, G.
Afiliação
  • Bhoday J; The Royal Marsden NHS Foundation Trust, Croydon University Hospital, Croydon, UK.
  • Glimelius B; Uppsala University, Uppsala, Sweden.
  • Tait D; The Royal Marsden NHS Foundation Trust, London, UK.
  • Glynne-Jones R; Mount Vernon Centre for Cancer Treatment, Middlesex, UK.
  • Adams R; Cardiff University and Velindre Cancer Centre, Cardiff, UK.
  • Brown G; The Royal Marsden NHS Foundation Trust, London, UK.
Colorectal Dis ; 20 Suppl 1: 97-99, 2018 05.
Article em En | MEDLINE | ID: mdl-29878687
Just over 50% of patients with advanced rectal cancer have a poor response to chemoradiotherapy with resultant poor outcomes. Professor Glimelius reviews the evidence base for defining such patients and the potential role, if any, of further treatment.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Terapia Neoadjuvante / Quimiorradioterapia Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Terapia Neoadjuvante / Quimiorradioterapia Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article